Tier 1 newswirereuters.com
India's Cipla misses second-quarter profit view on muted US sales
Cipla's second-quarter earnings fell short of expectations as weaker-than-anticipated sales in the US market for its generic Revlimid product exacerbated competitive pressures. This shortfall highlights ongoing challenges in the pharmaceutical sector, particularly for companies reliant on US revenues. The missed profit forecast signals potential headwinds for the broader Indian pharma market, raising concerns about future growth and profitability metrics.